Literature DB >> 19725789

Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections.

Stan Deresinski1.   

Abstract

Vancomycin is often combined with a second antibiotic, most often rifampin or gentamicin, for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Published data from experiments evaluating these and other vancomycin-based combinations, both in vitro and in animal models of infection, often yield inconsistent results, however. More importantly, no data are available from randomized clinical trials to support their use, and some regimens are known to have potential toxicities. Clinicians should carefully reconsider the use of vancomycin-based combination therapies for the treatment of infection due to methicillin-resistant S. aureus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19725789     DOI: 10.1086/605572

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  47 in total

1.  Mechanism-independent method for predicting response to multidrug combinations in bacteria.

Authors:  Kevin Wood; Satoshi Nishida; Eduardo D Sontag; Philippe Cluzel
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-05       Impact factor: 11.205

2.  Discovery and characterization of potent thiazoles versus methicillin- and vancomycin-resistant Staphylococcus aureus.

Authors:  Haroon Mohammad; Abdelrahman S Mayhoub; Adil Ghafoor; Muhammad Soofi; Ruba A Alajlouni; Mark Cushman; Mohamed N Seleem
Journal:  J Med Chem       Date:  2014-01-14       Impact factor: 7.446

3.  Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance.

Authors:  Stefany Moreno-Gamez; Alison L Hill; Daniel I S Rosenbloom; Dmitri A Petrov; Martin A Nowak; Pleuni S Pennings
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-18       Impact factor: 11.205

Review 4.  Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy.

Authors:  Ravina Kullar; James A McKinnell; George Sakoulas
Journal:  Clin Infect Dis       Date:  2014-07-21       Impact factor: 9.079

5.  Testing the optimality properties of a dual antibiotic treatment in a two-locus, two-allele model.

Authors:  Rafael Peña-Miller; Ayari Fuentes-Hernandez; Carlos Reding; Ivana Gudelj; Robert Beardmore
Journal:  J R Soc Interface       Date:  2014-05-08       Impact factor: 4.118

6.  Managing Severe Community-Acquired Pneumonia Due to Community Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Jason C Kwong; Kyra Chua; Patrick G P Charles
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

7.  Diffusion-driven enhancement of the antibiotic resistance selection window.

Authors:  Ayari Fuentes-Hernández; Anastasia Hernández-Koutoucheva; Alán F Muñoz; Raúl Domínguez Palestino; Rafael Peña-Miller
Journal:  J R Soc Interface       Date:  2019-09-11       Impact factor: 4.118

Review 8.  Coagulase-negative staphylococci.

Authors:  Karsten Becker; Christine Heilmann; Georg Peters
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

9.  Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.

Authors:  Jeffrey Fernandez; Darren Abbanat; Wenchi Shang; Wenping He; Karen Amsler; James Hastings; Anne Marie Queenan; John L Melton; Alfred M Barron; Robert K Flamm; A Simon Lynch
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

10.  Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant staphylococci.

Authors:  Haroon Mohammad; Abdelrahman S Mayhoub; Mark Cushman; Mohamed N Seleem
Journal:  J Antibiot (Tokyo)       Date:  2014-10-15       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.